个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Lin, G.[1] * ; Li, C.[2,3,4] ; Li, P. S.[5] ; Fang, W. Z.[6] ; Xu, H. P.[1] ; Gong, Y. H.[5] ; Zhu, Z. F.[7,8] ; Hu, Y.[9] ; Liang, W. H.[10,11,12] ; Chu, Q.[13] ; Zhong, W. Z.[14,15] ; Wu, L.[16] ; Wang, H. J.[17] ; Wang, Z. J.[18] ; Li, Z. M.[19] ; Lin, J.[20] ; Guan, Y. F.[5] ; Xia, X. F.[5] ; Yi, X.[5] ; Miao, Q.[1] ; Wu, B.[1] ; Jiang, K.[1] ; Zheng, X. B.[1] ; Zhu, W. F.[2] ; Zheng, X. L.[1] ; Huang, P. S.[3] ; Xiao, W. J.[3] ; Hu, D.[2] ; Zhang, L. F.[1] ; Fan, X. R.[1] ; Mok, T. S. K.[21,*1] ; Huang, C.[1] ;
单位： [1]Fujian Med Univ, Dept Thorac Oncol, Fuzhou, Peoples R China [2]Fujian Med Univ, Fujian Canc Hosp, Dept Pathol, Fuzhou, Peoples R China [3]Fujian Med Univ, Sch Basic Med Sci, Dept Pathol, Fuzhou, Peoples R China [4]Fujian Prov Key Lab Translat Canc Med, Fuzhou, Peoples R China [5]Geneplus Beijing, Beijing, Peoples R China [6]Fujian Med Univ, Hosp 900, Joint Logist Team, Dept Oncol,Clin Med Coll, Fuzhou, Peoples R China [7]Fudan Univ, Shanghai Canc Ctr, Dept Radiat Oncol, Shanghai, Peoples R China [8]Fudan Univ, Shanghai Med Sch, Dept Oncol, Shanghai, Peoples R China [9]Chinese Peoples Liberat Army Gen Hosp, Med Sch Chinese PLA, Dept Med Oncol, Beijing, Peoples R China [10]Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, Dept Thorac Oncol, Guangzhou, Peoples R China [11]China State Key Lab Resp Dis, Guangzhou, Peoples R China [12]Natl Clin Res Ctr Resp Dis, Guangzhou, Peoples R China [13]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Peoples R China [14]Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China [15]Guangdong Acad Med Sci, Guangzhou, Peoples R China [16]Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Dept Thorac Med Oncol, Changsha, Peoples R China [17]Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China [18]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Med Oncol,State Key Lab Mol Oncol, Beijing, Peoples R China [19]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China [20]Kunming Med Univ, Affiliated Hosp 2, Dept Med Oncol, Kunming, Yunnan, Peoples R China [21]Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China
出处：
DOI： 10.1016/j.annonc.2020.01.014
ISSN：

关键词： adenosquamous carcinoma clonal origin EGFR EGFR-TKI genomic profile

摘要：
Background: Adenosquamous carcinoma (ASC) of the lung is a heterogeneous disease that is composed of both adenocarcinoma components (ACC) and squamous cell carcinoma components (SCCC). Their genomic profile, genetic origin, and clinical management remain controversial. Patients and methods: Resected ASC and metastatic tumor in regional lymph nodes (Ms) were collected. The ACC and SCCC were separated by microdissection of primary tumor. The 1021 cancer-related genes were evaluated by next-generation sequencing independently in ACC and SCCC and LNs. Shared and private alterations in the two components were investigated. In addition, genomic profiles of independent cohorts of adenocarcinomas and squamous cell carcinomas were examined for comparison. We have also carried out a retrospective study of ASCs with known EGFR mutation status from 11 hospitals in China for their clinical outcomes. Results: The most frequent alterations in 28 surgically resected ASCs include EGFR (79%), TP53 (68%), MAP3K1 (14%) mutations, EGFR amplifications (32%), and MDM2 amplifications (18%). Twenty-seven patients (96%) had shared variations between ACC and SCCC, and pure SCCC metastases were not found in metastatic LNs among these patients. Only one patient with geographically separated ACC and SCCC had no shared mutations. Inter-component heterogeneity was a common genetic event of ACC and SCCC. The genomic profile of ASC was similar to that of 170 adenocarcinomas, but different from that of 62 squamous cell carcinomas. The incidence of EGFR mutations in the retrospective analysis of 517 ASCs was 51.8%. Among the 129 EGFR-positive patients who received EGFR-TKIs, the objective response rate was 56.6% and the median progression-free survival was 10.1 months (95% confidence interval: 9.0-11.2). Conclusions: The ACC and SCCC share a monoclonal origin, a majority with genetically inter-component heterogeneity. ASC may represent a subtype of adenocarcinoma with EGFR mutation being the most common genomic anomaly and sharing similar efficacy to EGFR TKI.

基金：
Joint Funds for the Innovation of Science and Technology, Fujian province, China [2017Y9083]; Fujian Provincial Health and Family Research Talent training program, Fujian province, China [2018CX-12]; Science and Technology Department guided projects, Fujian province, China [2018Y0016]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2018]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者：
第一作者单位： [1]Fujian Med Univ, Dept Thorac Oncol, Fuzhou, Peoples R China
通讯作者：
通讯机构： [21]Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China [*1]Chinese Univ Hong Kong, Dept Clin Oncol, Shatin, Hong Kong 999077, Peoples R China
推荐引用方式(GB/T 7714)：
Lin G.,Li C.,Li P. S.,et al.Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma[J].ANNALS OF ONCOLOGY.2020,31(4):517-524.doi:10.1016/j.annonc.2020.01.014.
APA：
Lin, G.,Li, C.,Li, P. S.,Fang, W. Z.,Xu, H. P....&Huang, C..(2020).Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.ANNALS OF ONCOLOGY,31,(4)
MLA：
Lin, G.,et al."Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma".ANNALS OF ONCOLOGY 31..4(2020):517-524

相关文献

[1]Genomic Origin and EGFR-TKI Efficacy of Pulmonary Adenosquamous Carcinoma [2]Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma (ARISE): A Multicenter, Open-Label, Single-Arm Trial [3]Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE) [4]Concomitant SBRT and EGFR-TKI Versus EGFR-TKI Alone for Oligometastatic NSCLC: A Multicenter, Randomized Phase II Study [5]EGFR-TKI不良反应管理专家共识 [6]Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer [7]Osimertinib (AZD9291) in Asia-Pacific Patients with T790M Mutation-Positive Advanced NSCLC: Open-Label Phase II Study Results [8]Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases [9]Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes [10]盐酸埃克替尼治疗190例晚期非小细胞肺癌疗效及不良反应

资源点击量：589 今日访问量：0 总访问量：441 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）